Exact Mass: 400.30494000000004

Exact Mass Matches: 400.30494000000004

Found 69 metabolites which its exact mass value is equals to given mass value 400.30494000000004, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Testosterone enanthate

[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate

C26H40O3 (400.297729)


testosterone enanthate is used in androgen substitution to replace testosterone at levels as close to physiological levels as is possible. For some androgen-dependent functions testosterone is a pro-hormone, peripherally converted to 5alpha-dihydrotestosterone (DHT) and 17beta-estradiol (E2), of which the levels preferably should be within normal physiological ranges. Furthermore, androgens should have a good safety profile without adverse effects on the prostate, serum lipids, liver or respiratory function, and they must be convenient to use and patient-friendly, with a relative independence from medical services. Natural testosterone is viewed as the best androgen for substitution in hypogonadal men. testosterone enanthate is used to treat male hypogonadism. Male hypogonadism is one of the most common endocrinologic syndromes. The diagnosis is based on clinical signs and symptoms plus laboratory confirmation via the measurement of low morning testosterone levels on two different occasions. Serum luteinizing hormone and follicle-stimulating hormone levels distinguish between primary (hypergonadotropic) and secondary (hypogonadotropic) hypogonadism. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. In primary hypogonadal men the on bone mineral density (BMD) responds dose dependently to testosterone substitution, whereas in secondary hypogonadism only testosterone enanthate treatment significantly increased the BMD. In all mammalian species studied to date, testosterone has been found to be the predominant intratesticular steroid. In volunteers receiving hormonal contraception by using a combination of testosterone enanthate and levonorgestrel, there is a profound reduction of both intratesticular testosterone concentration and androgen bioactivity. High doses of testosterone enanthate can normalize hematocrit values of maintenance hemodialysis patients with replenished bone marrow iron stores. testosterone enanthate is classified as a prohibited substance by the World Anti-Doping Agency (WADA) and its use may be detected by way of the urinary testosterone/epitestosterone (T/E) ratio. (PMID: 16185098, 16467270, 15329035, 17530941, 17484401, 4028529, 12792150) [HMDB] Testosterone enanthate is used in androgen substitution to replace testosterone at levels as close to physiological levels as is possible. For some androgen-dependent functions testosterone is a pro-hormone, peripherally converted to 5alpha-dihydrotestosterone (DHT) and 17beta-estradiol (E2), of which the levels preferably should be within normal physiological ranges. Furthermore, androgens should have a good safety profile without adverse effects on the prostate, serum lipids, liver or respiratory function, and they must be convenient to use and patient-friendly, with a relative independence from medical services. Natural testosterone is viewed as the best androgen for substitution in hypogonadal men. testosterone enanthate is used to treat male hypogonadism. Male hypogonadism is one of the most common endocrinologic syndromes. The diagnosis is based on clinical signs and symptoms plus laboratory confirmation via the measurement of low morning testosterone levels on two different occasions. Serum luteinizing hormone and follicle-stimulating hormone levels distinguish between primary (hypergonadotropic) and secondary (hypogonadotropic) hypogonadism. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. In primary hypogonadal men the on bone mineral density (BMD) responds dose dependently to testosterone substitution, whereas in secondary hypogonadism only testosterone enanthate treatment significantly increased the BMD. In all mammalian species studied to date, testosterone has been found to be the predominant intratesticular steroid. In volunteers receiving hormonal contraception by using a combination of testosterone enanthate and levonorgestrel, there is a profound reduction of both intratesticular testosterone concentration and androgen bioactivity. High doses of testosterone enanthate can normalize hematocrit values of maintenance hemodialysis patients with replenished bone marrow iron stores. testosterone enanthate is classified as a prohibited substance by the World Anti-Doping Agency (WADA) and its use may be detected by way of the urinary testosterone/epitestosterone (T/E) ratio. (PMID: 16185098, 16467270, 15329035, 17530941, 17484401, 4028529, 12792150). D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D000728 - Androgens C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C2360 - Anabolic Steroid

   

diapolycopene

(4E,6E,8E,10E,12E,14E,16E,18E,20E)-2,6,10,15,19,23-hexamethyltetracosa-2,4,6,8,10,12,14,16,18,20,22-undecaene

C30H40 (400.31298400000003)


   

17beta-Hydroxy-5alpha-androstan-3-one cyclohexanecarboxylate

17beta-Hydroxy-5alpha-androstan-3-one cyclohexanecarboxylate

C26H40O3 (400.297729)


   

Inecalcitol

5-{2-[1-(6-hydroxy-6-methylhept-4-yn-2-yl)-7a-methyl-hexahydro-1H-inden-4-ylidene]ethylidene}cyclohexane-1,3-diol

C26H40O3 (400.297729)


   

Prasterone enanthate

10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl heptanoate

C26H40O3 (400.297729)


   

13,16-Epoxy-25-hydroxy-17-cheilanthen-19,25-olide|Lintenolide C

13,16-Epoxy-25-hydroxy-17-cheilanthen-19,25-olide|Lintenolide C

C26H40O3 (400.297729)


   

Hyrtial

Hyrtial

C26H40O3 (400.297729)


A scalarane sesterterpenoid with formula C26H40O3, originally isolated from the marine sponge Hyrtios erecta.

   

isopseudolarifuroic acid B

isopseudolarifuroic acid B

C26H40O3 (400.297729)


   

(3beta,5alpha,8alpha,22E)-5,8-Epidioxy-24-norcholesta-6,22-dien-3-ol

(3beta,5alpha,8alpha,22E)-5,8-Epidioxy-24-norcholesta-6,22-dien-3-ol

C26H40O3 (400.297729)


   
   

17-oxoandrost-5-en-3-yl heptanoate

17-oxoandrost-5-en-3-yl heptanoate

C26H40O3 (400.297729)


   

11-Cycloheptylundecanoic acid beta-oxophenethyl ester

11-Cycloheptylundecanoic acid beta-oxophenethyl ester

C26H40O3 (400.297729)


   

3-hydroxy-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone|3alpha-hydroxy-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone

3-hydroxy-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone|3alpha-hydroxy-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone

C26H40O3 (400.297729)


   

4-(1-ethoxyethyl)-5-methyl-2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]benzene-1,3-diol

4-(1-ethoxyethyl)-5-methyl-2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]benzene-1,3-diol

C26H40O3 (400.297729)


   

(1R,2aR,6aS,7R,9aR,10aS,10bR)-7-[(1S,2Z)-1,5-dimethylhexa-2,4-dien-1-yl]-2,2a,4,6,6a,7,8,9,9a,10,10a,10b-dodecahydro-2a-methoxy-1,9a-dimethyl-1H-3-oxacyclopenta[5,6]cycloocta[1,2,3-cd]pentalen-1-ol|(5alpha,6alpha)-5-O-methylophiobolin H

(1R,2aR,6aS,7R,9aR,10aS,10bR)-7-[(1S,2Z)-1,5-dimethylhexa-2,4-dien-1-yl]-2,2a,4,6,6a,7,8,9,9a,10,10a,10b-dodecahydro-2a-methoxy-1,9a-dimethyl-1H-3-oxacyclopenta[5,6]cycloocta[1,2,3-cd]pentalen-1-ol|(5alpha,6alpha)-5-O-methylophiobolin H

C26H40O3 (400.297729)


   

3-hydroxy-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone

3-hydroxy-24,25,26,27-tetranortirucall-7-ene-23(21)-lactone

C26H40O3 (400.297729)


A tetracyclic triterpenoid found in Dysoxylum lenticellatum.

   

24,25,26,27-tetranor-3-oxo-9BetaH-lanosta-7-en-23-oic acid

24,25,26,27-tetranor-3-oxo-9BetaH-lanosta-7-en-23-oic acid

C26H40O3 (400.297729)


   

(20R)-3beta-Hydroxy-24,25,26,27-tetranor-5alpha-cycloartan-23,21-olide|3beta-3-Hydroxy-24,25,26,27-tetranorcycloartan-23,21-olide

(20R)-3beta-Hydroxy-24,25,26,27-tetranor-5alpha-cycloartan-23,21-olide|3beta-3-Hydroxy-24,25,26,27-tetranorcycloartan-23,21-olide

C26H40O3 (400.297729)


   

plakortone L

plakortone L

C26H40O3 (400.297729)


An organic heterobicyclic compound consisting of a gamma-lactone ring fused onto a substituted tetrahydrofuran ring. It is isolated from the Australian marine sponge Plakinastrella clathrata.

   

12beta-12-Hydroxy-24-methyl-24-oxo-16-scalaren-25-al-

12beta-12-Hydroxy-24-methyl-24-oxo-16-scalaren-25-al-

C26H40O3 (400.297729)


   

25-O-methylluffariellolide

25-O-methylluffariellolide

C26H40O3 (400.297729)


   

(5Z,7E,17E)-(1S,3R)-21-nor-9,10-seco-5,7,10(19),17-cholestatetraene-1,3,25-triol

(17E)-1α,25-dihydroxy-17,20-didehydro-21-norvitamin D3 / (17E)-1α,25-dihydroxy-17,20-didehydro-21-norcholecalciferol

C26H40O3 (400.297729)


   

(5Z,7E,17Z)-(1S,3R)-21-nor-9,10-seco-5,7,10(19),17-cholestatetraene-1,3,25-triol

(17Z)-1α,25-dihydroxy-17,20-didehydro-21-norvitamin D3 / (17Z)-1α,25-dihydroxy-17,20-didehydro-21-norcholecalciferol

C26H40O3 (400.297729)


   

19-Nor-14,20-bisepi-23-yne-1,25 dihydroxyvitamin D3

(7E)-(1R,3R,14R,20R)-23-yne-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol

C26H40O3 (400.297729)


   

19-Nor-14-epi-23-yne-1,25 dihydroxyvitamin D3

(7E)-(1R,3R,14R)-19-nor-23-yne-9,10-seco-5,7-cholestadiene-1,3,25-triol

C26H40O3 (400.297729)


   

DHEA ENANTHATE

[(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] heptanoate

C26H40O3 (400.297729)


   

ST 26:3;O3

17-heptanoyl-17beta-hydroxyandrost-4-en-3-one

C26H40O3 (400.297729)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D000728 - Androgens C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C2360 - Anabolic Steroid

   

TX 527

(7E)-(1R,3R,14R,20R)-23-yne-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol

C26H40O3 (400.297729)


   

Inecalcitol

5-[(2E)-2-[1-(6-hydroxy-6-methylhept-4-yn-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol

C26H40O3 (400.297729)


   
   

1,7-bis-(tert-Butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane

1,7-bis-(tert-Butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane

C20H40N4O4 (400.30494000000004)


   

17-(1-methoxycyclohexyl)oxy-10,13-dimethyl-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one

17-(1-methoxycyclohexyl)oxy-10,13-dimethyl-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one

C26H40O3 (400.297729)


   

4-HEPTADECYLUMBELLIFERONE

4-HEPTADECYLUMBELLIFERONE

C26H40O3 (400.297729)


   

3-Oxoandrost-4-en-17-yl heptanoate

3-Oxoandrost-4-en-17-yl heptanoate

C26H40O3 (400.297729)


   
   

(17E)-1alpha,25-dihydroxy-17,20-didehydro-21-norvitamin D3/(17E)-1alpha,25-dihydroxy-17,20-didehydro-21-norcholecalciferol

(17E)-1alpha,25-dihydroxy-17,20-didehydro-21-norvitamin D3/(17E)-1alpha,25-dihydroxy-17,20-didehydro-21-norcholecalciferol

C26H40O3 (400.297729)


   

27-Hydroxysterols

27-Hydroxysterols

C26H40O3 (400.297729)


   

Testosterone Enanthate

Testosterone Enanthate

C26H40O3 (400.297729)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D000728 - Androgens C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C2360 - Anabolic Steroid

   

(4E,6E,8E,10E,12E,14E,16E,18E,20E)-2,6,10,15,19,23-hexamethyltetracosa-2,4,6,8,10,12,14,16,18,20,22-undecaene

(4E,6E,8E,10E,12E,14E,16E,18E,20E)-2,6,10,15,19,23-hexamethyltetracosa-2,4,6,8,10,12,14,16,18,20,22-undecaene

C30H40 (400.31298400000003)


   

Hydroxyhexacosahexaenoic acid

Hydroxyhexacosahexaenoic acid

C26H40O3 (400.297729)


   
   

15-hydroxy-n-[2-(1h-indol-3-yl)ethyl]pentadecanimidic acid

15-hydroxy-n-[2-(1h-indol-3-yl)ethyl]pentadecanimidic acid

C25H40N2O2 (400.308962)


   

9-methoxy-3,15-dimethyl-6-(6-methylhepta-3,5-dien-2-yl)-12-oxatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadec-10-en-15-ol

9-methoxy-3,15-dimethyl-6-(6-methylhepta-3,5-dien-2-yl)-12-oxatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadec-10-en-15-ol

C26H40O3 (400.297729)


   

(4as,4br,6r,6ar,10as,10br,12as)-8-formyl-1,1,4a,6a,10b-pentamethyl-2,3,4,4b,5,6,7,10,10a,11,12,12a-dodecahydrochrysen-6-yl acetate

(4as,4br,6r,6ar,10as,10br,12as)-8-formyl-1,1,4a,6a,10b-pentamethyl-2,3,4,4b,5,6,7,10,10a,11,12,12a-dodecahydrochrysen-6-yl acetate

C26H40O3 (400.297729)


   

(1s,3r,6r,7s,9e,13r,15r,16r)-13-methoxy-3,15-dimethyl-6-[(2s,3z)-6-methylhepta-3,5-dien-2-yl]-12-oxatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadec-9-en-15-ol

(1s,3r,6r,7s,9e,13r,15r,16r)-13-methoxy-3,15-dimethyl-6-[(2s,3z)-6-methylhepta-3,5-dien-2-yl]-12-oxatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadec-9-en-15-ol

C26H40O3 (400.297729)


   

2-oxo-2-phenylethyl 11-cycloheptylundecanoate

2-oxo-2-phenylethyl 11-cycloheptylundecanoate

C26H40O3 (400.297729)


   

(1s,2r,5r,6r,9r,10r,13s,15s)-6,10-dimethyl-5-[(2r,3e)-5-methylhex-3-en-2-yl]-16,17-dioxapentacyclo[13.2.2.0¹,⁹.0²,⁶.0¹⁰,¹⁵]nonadec-18-en-13-ol

(1s,2r,5r,6r,9r,10r,13s,15s)-6,10-dimethyl-5-[(2r,3e)-5-methylhex-3-en-2-yl]-16,17-dioxapentacyclo[13.2.2.0¹,⁹.0²,⁶.0¹⁰,¹⁵]nonadec-18-en-13-ol

C26H40O3 (400.297729)


   

4-{7-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}oxolan-2-one

4-{7-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}oxolan-2-one

C26H40O3 (400.297729)


   

(4r)-4-[(1s,3r,6s,8r,11s,12s,15r,16r)-6-hydroxy-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]oxolan-2-one

(4r)-4-[(1s,3r,6s,8r,11s,12s,15r,16r)-6-hydroxy-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl]oxolan-2-one

C26H40O3 (400.297729)


   

(3s)-3-[(1s,3as,5ar,9ar,9br,11as)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,5h,5ah,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]butanoic acid

(3s)-3-[(1s,3as,5ar,9ar,9br,11as)-3a,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,3h,5h,5ah,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]butanoic acid

C26H40O3 (400.297729)


   

5,6a-dimethyl-5-(12-phenyldodecyl)-dihydro-3h-furo[3,2-b]furan-2-one

5,6a-dimethyl-5-(12-phenyldodecyl)-dihydro-3h-furo[3,2-b]furan-2-one

C26H40O3 (400.297729)


   

4-[(1r)-1-ethoxyethyl]-5-methyl-2-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]benzene-1,3-diol

4-[(1r)-1-ethoxyethyl]-5-methyl-2-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]benzene-1,3-diol

C26H40O3 (400.297729)


   

4-[(3e,7e)-4,8-dimethyl-10-(2,6,6-trimethylcyclohex-1-en-1-yl)deca-3,7-dien-1-yl]-5-methoxy-5h-furan-2-one

4-[(3e,7e)-4,8-dimethyl-10-(2,6,6-trimethylcyclohex-1-en-1-yl)deca-3,7-dien-1-yl]-5-methoxy-5h-furan-2-one

C26H40O3 (400.297729)


   

4-{6-hydroxy-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl}oxolan-2-one

4-{6-hydroxy-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-15-yl}oxolan-2-one

C26H40O3 (400.297729)


   

(1s,3r,6r,7s,9s,13s,15r,16s)-9-methoxy-3,15-dimethyl-6-[(2s,3z)-6-methylhepta-3,5-dien-2-yl]-12-oxatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadec-10-en-15-ol

(1s,3r,6r,7s,9s,13s,15r,16s)-9-methoxy-3,15-dimethyl-6-[(2s,3z)-6-methylhepta-3,5-dien-2-yl]-12-oxatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadec-10-en-15-ol

C26H40O3 (400.297729)


   

3-{7-hydroxy-1,6,6,9a,11a-pentamethyl-2h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}butanoic acid

3-{7-hydroxy-1,6,6,9a,11a-pentamethyl-2h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}butanoic acid

C26H40O3 (400.297729)


   

4-(1-ethoxyethyl)-5-methyl-2-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)benzene-1,3-diol

4-(1-ethoxyethyl)-5-methyl-2-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)benzene-1,3-diol

C26H40O3 (400.297729)


   

(4s)-4-[(1s,3as,5ar,7r,9ar,9br,11as)-7-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]oxolan-2-one

(4s)-4-[(1s,3as,5ar,7r,9ar,9br,11as)-7-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]oxolan-2-one

C26H40O3 (400.297729)


   

(1s,3r,6r,7s,13s,15r,16s)-13-methoxy-3,15-dimethyl-6-[(2s)-6-methylhepta-3,5-dien-2-yl]-12-oxatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadec-9-en-15-ol

(1s,3r,6r,7s,13s,15r,16s)-13-methoxy-3,15-dimethyl-6-[(2s)-6-methylhepta-3,5-dien-2-yl]-12-oxatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadec-9-en-15-ol

C26H40O3 (400.297729)


   

(5r)-5-[(1s,3ar,5ar,7r,9ar,9br,11ar)-7-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]oxolan-2-one

(5r)-5-[(1s,3ar,5ar,7r,9ar,9br,11ar)-7-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]oxolan-2-one

C26H40O3 (400.297729)


   

(1r,2s,4s,10s,11s,13r,14s,19s)-10-methoxy-1,11,14,18,18-pentamethyl-8-oxapentacyclo[11.8.0.0²,¹¹.0⁵,⁹.0¹⁴,¹⁹]henicosa-5(9),6-dien-4-ol

(1r,2s,4s,10s,11s,13r,14s,19s)-10-methoxy-1,11,14,18,18-pentamethyl-8-oxapentacyclo[11.8.0.0²,¹¹.0⁵,⁹.0¹⁴,¹⁹]henicosa-5(9),6-dien-4-ol

C26H40O3 (400.297729)


   

(1s,3r,6r,7s,13r,15r,16r)-13-methoxy-3,15-dimethyl-6-[(2s)-6-methylhepta-3,5-dien-2-yl]-12-oxatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadec-9-en-15-ol

(1s,3r,6r,7s,13r,15r,16r)-13-methoxy-3,15-dimethyl-6-[(2s)-6-methylhepta-3,5-dien-2-yl]-12-oxatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadec-9-en-15-ol

C26H40O3 (400.297729)


   

(1s,3r,6r,7s,9e,13s,15r,16s)-13-methoxy-3,15-dimethyl-6-[(2s,3z)-6-methylhepta-3,5-dien-2-yl]-12-oxatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadec-9-en-15-ol

(1s,3r,6r,7s,9e,13s,15r,16s)-13-methoxy-3,15-dimethyl-6-[(2s,3z)-6-methylhepta-3,5-dien-2-yl]-12-oxatetracyclo[8.5.1.0³,⁷.0¹³,¹⁶]hexadec-9-en-15-ol

C26H40O3 (400.297729)


   

6,10-dimethyl-5-(5-methylhex-3-en-2-yl)-16,17-dioxapentacyclo[13.2.2.0¹,⁹.0²,⁶.0¹⁰,¹⁵]nonadec-18-en-13-ol

6,10-dimethyl-5-(5-methylhex-3-en-2-yl)-16,17-dioxapentacyclo[13.2.2.0¹,⁹.0²,⁶.0¹⁰,¹⁵]nonadec-18-en-13-ol

C26H40O3 (400.297729)


   

4-(1-ethoxyethyl)-5-methyl-2-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]benzene-1,3-diol

4-(1-ethoxyethyl)-5-methyl-2-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]benzene-1,3-diol

C26H40O3 (400.297729)


   

(3r)-3-[(1s,5ar,7r,9ar,9bs,11as)-7-hydroxy-1,6,6,9a,11a-pentamethyl-2h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]butanoic acid

(3r)-3-[(1s,5ar,7r,9ar,9bs,11as)-7-hydroxy-1,6,6,9a,11a-pentamethyl-2h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]butanoic acid

C26H40O3 (400.297729)